Hung Trinh: Making Strides Toward Off-the-Shelf CAR T Cell Therapy for Cancer
Hung Trinh, CMC/MFG Consultant and Managing Director at Vertex Biopharm Consulting, shared on LinkedIn:
Making Strides Toward Off-the-Shelf CAR T Cell Therapy for Cancer
Their findings are published in Nature in an article titled, “HIV immune evasin Nef enhances allogeneic CAR T cell potency.”
“Autologous chimeric antigen receptor (CAR) T cells are a genetically engineered therapy that is highly effective against B cell malignancies and multiple myeloma,” the researchers wrote. “However, the length and cost of personalized manufacturing limits access and leaves patients vulnerable to disease progression. Allogeneic cell therapies have the potential to increase patient access and improve treatment outcomes but are limited by immune rejection. To devise a strategy to protect allogeneic CAR T cells from host immune cells, we turned to lymphotropic viruses that have evolved integrated mechanisms for immune escape of virus-infected lymphocytes.”
The research identifies a way to modify the donor CAR T cells, called allogeneic CAR T cells, so that they won’t be rejected by the patient receiving them and will persist in fighting the cancer.
The new approach involves equipping the CAR T cells with a protein called Nef. The researchers showed that inserting Nef into donor CAR T cells enabled the cells to survive and remain potent in a mouse model for cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023